# Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial Cancer

> **NCT06892860** · PHASE2 · RECRUITING · sponsor: **Queen Mary University of London** · enrollment: 320 (estimated)

## Conditions studied

- Urinary Bladder Neoplasms

## Interventions

- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT06892860
- **Lead sponsor:** Queen Mary University of London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-16
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-12-22
- **Target enrollment:** 320 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06892860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06892860, "Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06892860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*